Plain-English translation of NCT07368153 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing an IDO-1 inhibitor—a new medication—to see if it can safely prevent serious complications from Epstein-Barr virus (EBV) in kidney transplant patients. The study focuses on people who don't currently have EBV but are receiving a kidney from a donor who does, which puts them at higher risk for problems. Researchers want to know if this medication is safe and well-tolerated when given alongside the standard medicines transplant patients already take.
Kidney transplant recipients must take strong medications to prevent their body from rejecting the new organ, but these same medications weaken the immune system and make serious infections more likely. This study exists because people who receive kidneys from EBV-positive donors face a particularly high risk of developing severe EBV-related complications, and this medication may offer a way to reduce that risk.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive either the new medication or a placebo (inactive pill) along with your standard transplant medications, starting before or on the day of your surgery. The study team will give you the medication for a defined treatment period and then monitor your safety for several months afterward. You will have regular check-ins, blood tests, and follow-up visits to make sure the medication is safe and to watch for any side effects or complications.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
Switzerland